TOFACITINIB CITRATE
- Product NDC
- 68254-5012
- Requested package NDC
- 68254-5012-3
- 11-digit product format
- 682545012
- Labeler code
- 68254
- Product ID
- 68254-5012_ad6e5467-da25-405d-a725-c95489d79aab
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- TOFACITINIB CITRATE
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- CONCORD BIOTECH LIMITED
- Application
- ANDA218821
- Marketing category
- ANDA
- Marketing start
- 2026-10-01
- Substance
- TOFACITINIB CITRATE
- Active strength
- 16.16 mg/1
- Pharmacologic classes
- Janus Kinase Inhibitor [EPC], Janus Kinase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218821-001 | TOFACITINIB CITRATE | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | |
| A218821-002 | TOFACITINIB CITRATE | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218821-001 | AB |
| A218821-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218821-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | A218821-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | A218821-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | A218821-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A218821-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A218821-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A218821-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A218821-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218821-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-09 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218821-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-09 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | A218821-001 | AB | 1 | d4dbc9d85df4… |
| 2026-11-14 07:37:17 | 2026-10 | A218821-002 | AB | 1 | d4dbc9d85df4… |
| 2026-10-15 13:18:30 | 2026-09 | A218821-001 | AB | 1 | c2088c7a36db… |
| 2026-10-15 13:18:30 | 2026-09 | A218821-002 | AB | 1 | c2088c7a36db… |
| 2026-09-14 22:38:34 | 2026-08 | A218821-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A218821-002 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A218821-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A218821-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218821-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218821-002 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- TOFACITINIB CITRATE
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| TOFACITINIB CITRATE | 16.16 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| O1FF4DIV0D | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 6c33e5b4-4843-4a80-a4f8-435bfceddc2a | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE | TOFACITINIB CITRATE | Stellon Biotech Inc. | 89eb2ffc-02d9-4b46-b480-e9b10af33027 | 2026-10-16 | Boxed warning, Warnings, Adverse reactions | 218821 ANDA218821 |
| TOFACITINIB CITRATE | TOFACITINIB CITRATE | CONCORD BIOTECH LIMITED | 6c33e5b4-4843-4a80-a4f8-435bfceddc2a | 2026-10-16 | Boxed warning, Warnings, Adverse reactions | 218821 ANDA218821 68254-5012-3 68254-5012 68254501203 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 68254-5012-3 | 68254501203 | 180 TABLET, FILM COATED in 1 BOTTLE (68254-5012-3) | 2026-10-01 | No | No | Current |